New drug combo for MDS or AML with TP53 gene changes
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of two drugs, ropeginterferon alfa-2b and azacitidine, for people with MDS or AML who have a change in the TP53 gene. The goal is to see if this combination can help control the disease and possibly improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of MDS or AML with a TP53 gene mutation (a specific genetic change).
- For one group: the disease has not improved or has returned after treatment (R/R) and you are not eligible for intensive chemotherapy due to age (60 or older) or health conditions.
- Your liver function must be within acceptable limits (certain blood test results).
- If you are of childbearing age, you must agree to use effective birth control during the trial and for 4 months after the last dose.
- You must be willing to sign a consent form and follow the study requirements.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called APG1252 combined with azacitidine (AZA) for people with high-risk AML or certain related blood cancers. The goal is to see if the combination works better than standard treatments.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This trial tests a new drug, rezatapopt, combined with azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. It is only for people whose cancer cells have a specific change in a gene called TP53 (the Y220C mutation). The goal is to see if this combination can help control the disease.
This trial tests a new drug (axatilimab) combined with two standard chemotherapy drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has a TP53 mutation. The goal is to see if this combination helps control the cancer better than current treatments.
This study tests a combination of two drugs, azacitidine and rotercept, for people with a type of blood cancer called myelodysplastic syndrome (MDS) that has a higher risk of progressing. The goal is to see if adding rotercept helps control the disease better than standard care.
This study tests a medication called ropeginterferon alfa-2b for people with certain blood cancers that have features of both myelodysplastic syndromes and myeloproliferative neoplasms. The drug may help control blood counts and reduce symptoms.
Hear when a new Ropeginterferon trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.